BlackRock Inc. increased its holdings in shares of Aravive Inc (NASDAQ:ARAV) by 5.8% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 173,943 shares of the company’s stock after purchasing an additional 9,544 shares during the period. BlackRock Inc. owned 1.54% of Aravive worth $1,044,000 as of its most recent filing with the SEC.
Separately, Renaissance Technologies LLC grew its holdings in Aravive by 13.8% during the second quarter. Renaissance Technologies LLC now owns 148,265 shares of the company’s stock worth $890,000 after purchasing an additional 18,017 shares during the period. 28.35% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:ARAV opened at $6.48 on Tuesday. Aravive Inc has a 12-month low of $3.07 and a 12-month high of $9.72. The stock has a market cap of $70.02 million, a PE ratio of -0.61 and a beta of 2.21. The business has a 50 day moving average of $6.93 and a 200-day moving average of $6.26. The company has a quick ratio of 11.28, a current ratio of 11.28 and a debt-to-equity ratio of 0.17.
Aravive (NASDAQ:ARAV) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.27. The firm had revenue of $3.05 million for the quarter, compared to the consensus estimate of $1.00 million. Equities research analysts expect that Aravive Inc will post -1.68 earnings per share for the current year.
In other news, CEO Jay Shepard sold 4,004 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $6.82, for a total transaction of $27,307.28. Insiders own 39.80% of the company’s stock.
A number of equities analysts recently commented on the company. HC Wainwright assumed coverage on Aravive in a report on Thursday, October 10th. They set a “buy” rating and a $18.00 price target for the company. ValuEngine cut Aravive from a “strong-buy” rating to a “buy” rating in a report on Monday, October 21st. Zacks Investment Research cut Aravive from a “buy” rating to a “hold” rating in a report on Thursday, October 24th. Finally, Piper Jaffray Companies set a $15.00 price objective on Aravive and gave the stock a “buy” rating in a report on Friday, September 27th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $13.69.
Aravive Company Profile
Aravive, Inc, a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer.
Featured Story: How is the S&P 500 index different from the DJIA?
Want to see what other hedge funds are holding ARAV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aravive Inc (NASDAQ:ARAV).
Receive News & Ratings for Aravive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aravive and related companies with MarketBeat.com's FREE daily email newsletter.